AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
Related to this article
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
Advertisement
Advertisement
Trending on AJMC
1
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
2
GOLD COPD Conference Turns to Earlier Diagnosis and Proactive Care
3
4 Things for Payers and Consumers to Watch on Election Day
4
Germline Testing Finds More Mutations in Select Patients With Lung Cancer
5